Olsson H
Department of Oncology, University Hospital, Lund, Sweden.
J Mammary Gland Biol Neoplasia. 2000 Jul;5(3):283-7. doi: 10.1023/a:1009546811429.
Male breast cancer is a rare disease and clinical or epidemiological data are available from only a relatively few cases. Nonetheless, both similarities and discrepancies are apparent between breast cancer in men and women. For example, lobular and mucinous carcinomas are seldom seen in men. Tumors in men more often display neuroendocrine differentiation, with an average age at diagnosis ten years later than in women. A high proportion of breast tumors in men are estrogen receptor-alpha positive (in this review 77%) and progesterone receptor positive (76%). Breast tumors in men often respond favorably to endocrine manipulation, including testicular ablation or antiestrogen therapy. Thus, the hormone receptors in these tumors can be functionally active and used for therapeutic intervention. This proposal has been questioned in some studies because estrogen dependent proteins are expressed to a lesser degree in men. Furthermore, men do not have a better overall breast cancer prognosis compared with women, after adjustments have been made for age and tumor stage. While the androgen receptor content has been assessed in a few studies, there are no studies on the estrogen receptor-beta content of breast tumors in men.
男性乳腺癌是一种罕见疾病，临床或流行病学数据仅来自相对较少的病例。尽管如此，男性乳腺癌和女性乳腺癌之间的异同都很明显。例如，小叶癌和黏液癌在男性中很少见。男性肿瘤更常表现出神经内分泌分化，诊断时的平均年龄比女性晚十年。男性乳腺癌中很大一部分是雌激素受体α阳性（本综述中为77%）和孕激素受体阳性（76%）。男性乳腺癌通常对内分泌治疗反应良好，包括睾丸切除或抗雌激素治疗。因此，这些肿瘤中的激素受体可能具有功能活性，可用于治疗干预。这一观点在一些研究中受到质疑，因为雌激素依赖性蛋白在男性中的表达程度较低。此外，在对年龄和肿瘤分期进行调整后，男性乳腺癌的总体预后并不比女性好。虽然在一些研究中评估了雄激素受体含量，但尚无关于男性乳腺肿瘤雌激素受体β含量的研究。
